The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Tumour-cell Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
Tumour-cell vaccines which contain tumour cells obtained from the patient following surgery are intended to prevent disease recurrence in patients who have received prior treatment.
The global Tumour-cell Vaccine market size is expected to reach US$ 345 million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. The market is mainly driven by the significant applications of Tumour-cell Vaccine in various end use industries. The expanding demands from the Pediatrics and Adults, are propelling Tumour-cell Vaccine market. MVax, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the OncoVAX segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Tumour-cell Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Tumour-cell Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Tumour-cell Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Tumour-cell Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Tumour-cell Vaccine covered in this report include AVAX Technologies, Vaccinogen, Biovest, Aduro BioTech and Regeneus, etc.
The global Tumour-cell Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AVAX Technologies
Vaccinogen
Biovest
Aduro BioTech
Regeneus
Global Tumour-cell Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Tumour-cell Vaccine market, Segment by Type:
MVax
OncoVAX
BiovaxID
Others
Global Tumour-cell Vaccine market, by Application
Pediatrics
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Tumour-cell Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Tumour-cell Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Tumour-cell vaccines which contain tumour cells obtained from the patient following surgery are intended to prevent disease recurrence in patients who have received prior treatment.
The global Tumour-cell Vaccine market size is expected to reach US$ 345 million by 2029, growing at a CAGR of 5.8% from 2023 to 2029. The market is mainly driven by the significant applications of Tumour-cell Vaccine in various end use industries. The expanding demands from the Pediatrics and Adults, are propelling Tumour-cell Vaccine market. MVax, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the OncoVAX segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Tumour-cell Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Tumour-cell Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Tumour-cell Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Tumour-cell Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Tumour-cell Vaccine covered in this report include AVAX Technologies, Vaccinogen, Biovest, Aduro BioTech and Regeneus, etc.
The global Tumour-cell Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AVAX Technologies
Vaccinogen
Biovest
Aduro BioTech
Regeneus
Global Tumour-cell Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Tumour-cell Vaccine market, Segment by Type:
MVax
OncoVAX
BiovaxID
Others
Global Tumour-cell Vaccine market, by Application
Pediatrics
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Tumour-cell Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Tumour-cell Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Tumour-cell Vaccine Market Overview
1.1 Tumour-cell Vaccine Product Overview
1.2 Tumour-cell Vaccine Market Segment by Type
1.2.1 MVax
1.2.2 OncoVAX
1.2.3 BiovaxID
1.2.4 Others
1.3 Global Tumour-cell Vaccine Market Size by Type
1.3.1 Global Tumour-cell Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Tumour-cell Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Tumour-cell Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Tumour-cell Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Tumour-cell Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Tumour-cell Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Tumour-cell Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Tumour-cell Vaccine Sales Breakdown by Type (2018-2023)
2 Global Tumour-cell Vaccine Market Competition by Company
2.1 Global Top Players by Tumour-cell Vaccine Sales (2018-2023)
2.2 Global Top Players by Tumour-cell Vaccine Revenue (2018-2023)
2.3 Global Top Players by Tumour-cell Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Tumour-cell Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Tumour-cell Vaccine Market Competitive Situation and Trends
2.5.1 Tumour-cell Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Tumour-cell Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tumour-cell Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Tumour-cell Vaccine Market
2.8 Key Manufacturers Tumour-cell Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Tumour-cell Vaccine Status and Outlook by Region
3.1 Global Tumour-cell Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Tumour-cell Vaccine Historic Market Size by Region
3.2.1 Global Tumour-cell Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Tumour-cell Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Tumour-cell Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Tumour-cell Vaccine Forecasted Market Size by Region
3.3.1 Global Tumour-cell Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Tumour-cell Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Tumour-cell Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Tumour-cell Vaccine by Application
4.1 Tumour-cell Vaccine Market Segment by Application
4.1.1 Pediatrics
4.1.2 Adults
4.2 Global Tumour-cell Vaccine Market Size by Application
4.2.1 Global Tumour-cell Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Tumour-cell Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Tumour-cell Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Tumour-cell Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Tumour-cell Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Tumour-cell Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Tumour-cell Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Tumour-cell Vaccine Sales Breakdown by Application (2018-2023)
5 North America Tumour-cell Vaccine by Country
5.1 North America Tumour-cell Vaccine Historic Market Size by Country
5.1.1 North America Tumour-cell Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Tumour-cell Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Tumour-cell Vaccine Sales in Value by Country (2018-2023)
5.2 North America Tumour-cell Vaccine Forecasted Market Size by Country
5.2.1 North America Tumour-cell Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Tumour-cell Vaccine Sales in Value by Country (2024-2029)
6 Europe Tumour-cell Vaccine by Country
6.1 Europe Tumour-cell Vaccine Historic Market Size by Country
6.1.1 Europe Tumour-cell Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Tumour-cell Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Tumour-cell Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Tumour-cell Vaccine Forecasted Market Size by Country
6.2.1 Europe Tumour-cell Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Tumour-cell Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Tumour-cell Vaccine by Region
7.1 Asia-Pacific Tumour-cell Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Tumour-cell Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Tumour-cell Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Tumour-cell Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Tumour-cell Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Tumour-cell Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Tumour-cell Vaccine Sales in Value by Region (2024-2029)
8 Latin America Tumour-cell Vaccine by Country
8.1 Latin America Tumour-cell Vaccine Historic Market Size by Country
8.1.1 Latin America Tumour-cell Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Tumour-cell Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Tumour-cell Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Tumour-cell Vaccine Forecasted Market Size by Country
8.2.1 Latin America Tumour-cell Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Tumour-cell Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Tumour-cell Vaccine by Country
9.1 Middle East and Africa Tumour-cell Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Tumour-cell Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Tumour-cell Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Tumour-cell Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Tumour-cell Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Tumour-cell Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Tumour-cell Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 AVAX Technologies
10.1.1 AVAX Technologies Company Information
10.1.2 AVAX Technologies Introduction and Business Overview
10.1.3 AVAX Technologies Tumour-cell Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 AVAX Technologies Tumour-cell Vaccine Products Offered
10.1.5 AVAX Technologies Recent Development
10.2 Vaccinogen
10.2.1 Vaccinogen Company Information
10.2.2 Vaccinogen Introduction and Business Overview
10.2.3 Vaccinogen Tumour-cell Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Vaccinogen Tumour-cell Vaccine Products Offered
10.2.5 Vaccinogen Recent Development
10.3 Biovest
10.3.1 Biovest Company Information
10.3.2 Biovest Introduction and Business Overview
10.3.3 Biovest Tumour-cell Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Biovest Tumour-cell Vaccine Products Offered
10.3.5 Biovest Recent Development
10.4 Aduro BioTech
10.4.1 Aduro BioTech Company Information
10.4.2 Aduro BioTech Introduction and Business Overview
10.4.3 Aduro BioTech Tumour-cell Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Aduro BioTech Tumour-cell Vaccine Products Offered
10.4.5 Aduro BioTech Recent Development
10.5 Regeneus
10.5.1 Regeneus Company Information
10.5.2 Regeneus Introduction and Business Overview
10.5.3 Regeneus Tumour-cell Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Regeneus Tumour-cell Vaccine Products Offered
10.5.5 Regeneus Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Tumour-cell Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Tumour-cell Vaccine Industrial Chain Analysis
11.4 Tumour-cell Vaccine Market Dynamics
11.4.1 Tumour-cell Vaccine Industry Trends
11.4.2 Tumour-cell Vaccine Market Drivers
11.4.3 Tumour-cell Vaccine Market Challenges
11.4.4 Tumour-cell Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Tumour-cell Vaccine Distributors
12.3 Tumour-cell Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
